We found that RASSF1A was hypermethylated in approximately 85% of all invasive tumors and DCIS, and our results are in agreement with such a high incidence of RASSF1A methylation [18-20]. This evidence concerns the gene RASSF1 and ductal breast carcinoma in situ.